Lisa K Hicks,Hans J Messersmith,Samer Al Hadidi,Rahul Banerjee,Benjamin A Derman,Shaji Kumar,Tanya M Wildes,Susan Bal,Sita Bhella,Cynthia Chmielewski,Caitlin Costello,Raetasha Dabney,Monique Hartley-Brown,Alan Langerak,Brea Lipe,Thomas Martin,Arleigh McCurdy,Hira Mian,Eloisa Riva,Rahul Seth,Latha Subramanian,Joseph Mikhael
PURPOSETo provide updated guidance regarding the therapy for multiple myeloma.METHODSASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.RESULTSThe updated review identified a total of 161 relevant randomized trials.UPDATED RECOMMENDATIONSDaratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.
{"title":"Treatment of Multiple Myeloma: ASCO-Ontario Health (Cancer Care Ontario) Living Guideline.","authors":"Lisa K Hicks,Hans J Messersmith,Samer Al Hadidi,Rahul Banerjee,Benjamin A Derman,Shaji Kumar,Tanya M Wildes,Susan Bal,Sita Bhella,Cynthia Chmielewski,Caitlin Costello,Raetasha Dabney,Monique Hartley-Brown,Alan Langerak,Brea Lipe,Thomas Martin,Arleigh McCurdy,Hira Mian,Eloisa Riva,Rahul Seth,Latha Subramanian,Joseph Mikhael","doi":"10.1200/jco-25-02587","DOIUrl":"https://doi.org/10.1200/jco-25-02587","url":null,"abstract":"PURPOSETo provide updated guidance regarding the therapy for multiple myeloma.METHODSASCO and Ontario Health (Cancer Care Ontario) convened a joint Expert Panel and conducted an updated systematic review of the literature.RESULTSThe updated review identified a total of 161 relevant randomized trials.UPDATED RECOMMENDATIONSDaratumumab therapy may be offered to patients with high-risk smoldering myeloma. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as initial therapy for transplant eligible patients. They should also be offered at least lenalidomide maintenance, with or without daratumumab, carfilzomib, and/or dexamethasone. Quadruplet therapy with daratumumab or isatuximab, combined with bortezomib, lenalidomide, and dexamethasone, should be offered as therapy for suitable transplant-ineligible patients. Patients with relapsed or refractory multiple myeloma should be offered triplet therapy or T-cell redirecting therapies according to a set of recommended principles.Additional information is available at www.asco.org/hematologic-malignancies-guidelines.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"98 1","pages":"JCO2502587"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907530","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Kevin T Liou,Joke Bradt,M Beatriz Currier,Raymond Baser,Katherine Panageas,Jodi MacLeod,Desiree Walker,Susan Q Li,Ana Maria Lopez,Kelly McConnell,Jun J Mao
PURPOSEAnxiety is prevalent, disruptive, and undertreated among cancer survivors. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have access, respond to treatment, or prefer this option because of stigma. Music therapy is effective for short-term anxiety reduction, but it is unknown whether it is noninferior to first-line CBT for long-term anxiety reduction.METHODSThis comparative effectiveness trial randomly assigned English- or Spanish-speaking cancer survivors to seven weekly telehealth sessions of music therapy or CBT. The coprimary end points were changes in the Hospital Anxiety and Depression Scale (HADS) anxiety score at weeks 8 and 26. The noninferiority margin was 0.35 standard deviations, informed by a minimal clinically important difference (MCID) of 1.7 points. Secondary outcomes included fatigue, depression, insomnia, pain, cognitive dysfunction, and health-related quality of life.RESULTSAmong N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was Hispanic. At week 8, the mean change in HADS anxiety score was -3.12 (95% CI, -3.59 to -2.65) in music therapy and -2.97 (95% CI, -3.45 to -2.50) in CBT; the between-group difference was -0.15 (95% CI, -0.78 to 0.49), within the noninferiority margin of 1.20 (P < .001). At week 26, the mean change was -3.31 (95% CI, -3.78 to -2.85) in music therapy and -3.00 (95% CI, -3.47 to -2.53) in CBT; the between-group difference was -0.31 (95% CI, -0.95 to 0.32), within the noninferiority margin of 1.28 (P < .001). Both groups produced anxiety reductions exceeding the MCID and showed similar improvements in secondary outcomes.CONCLUSIONMusic therapy is noninferior to CBT for anxiety in cancer survivors. Both telehealth interventions produced clinically meaningful, durable improvements in anxiety.
{"title":"Music Therapy Versus Cognitive Behavioral Therapy via Telehealth for Anxiety in Cancer Survivors: A Randomized Clinical Trial.","authors":"Kevin T Liou,Joke Bradt,M Beatriz Currier,Raymond Baser,Katherine Panageas,Jodi MacLeod,Desiree Walker,Susan Q Li,Ana Maria Lopez,Kelly McConnell,Jun J Mao","doi":"10.1200/jco-25-00726","DOIUrl":"https://doi.org/10.1200/jco-25-00726","url":null,"abstract":"PURPOSEAnxiety is prevalent, disruptive, and undertreated among cancer survivors. Cognitive behavioral therapy (CBT) is the first-line treatment, but not all individuals have access, respond to treatment, or prefer this option because of stigma. Music therapy is effective for short-term anxiety reduction, but it is unknown whether it is noninferior to first-line CBT for long-term anxiety reduction.METHODSThis comparative effectiveness trial randomly assigned English- or Spanish-speaking cancer survivors to seven weekly telehealth sessions of music therapy or CBT. The coprimary end points were changes in the Hospital Anxiety and Depression Scale (HADS) anxiety score at weeks 8 and 26. The noninferiority margin was 0.35 standard deviations, informed by a minimal clinically important difference (MCID) of 1.7 points. Secondary outcomes included fatigue, depression, insomnia, pain, cognitive dysfunction, and health-related quality of life.RESULTSAmong N = 300 patients, 74.7% was female, 76.5% was White, and 19.0% was Hispanic. At week 8, the mean change in HADS anxiety score was -3.12 (95% CI, -3.59 to -2.65) in music therapy and -2.97 (95% CI, -3.45 to -2.50) in CBT; the between-group difference was -0.15 (95% CI, -0.78 to 0.49), within the noninferiority margin of 1.20 (P < .001). At week 26, the mean change was -3.31 (95% CI, -3.78 to -2.85) in music therapy and -3.00 (95% CI, -3.47 to -2.53) in CBT; the between-group difference was -0.31 (95% CI, -0.95 to 0.32), within the noninferiority margin of 1.28 (P < .001). Both groups produced anxiety reductions exceeding the MCID and showed similar improvements in secondary outcomes.CONCLUSIONMusic therapy is noninferior to CBT for anxiety in cancer survivors. Both telehealth interventions produced clinically meaningful, durable improvements in anxiety.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"105 1","pages":"JCO2500726"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907529","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
A reflection by @SondosZayedMD on the unexpected power of saying "I don't know"-and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_ASCO.
{"title":"The Power of \"I Don't Know\".","authors":"Sondos Zayed","doi":"10.1200/jco-25-02489","DOIUrl":"https://doi.org/10.1200/jco-25-02489","url":null,"abstract":"A reflection by @SondosZayedMD on the unexpected power of saying \"I don't know\"-and how honest uncertainty can deepen trust, guide care, and create space for what truly matters in oncology. #JCO @JCO_ASCO.","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"13 1","pages":"JCO2502489"},"PeriodicalIF":45.3,"publicationDate":"2026-01-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145907531","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Therapeutic Considerations in Early-Stage, Estrogen Receptor-Positive, BRCA-Associated Breast Cancer.","authors":"Susan M Domchek","doi":"10.1200/jco-25-02428","DOIUrl":"https://doi.org/10.1200/jco-25-02428","url":null,"abstract":"","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"63 1","pages":"JCO2502428"},"PeriodicalIF":45.3,"publicationDate":"2026-01-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145903670","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS609-TPS609, January 2026.
临床肿瘤学杂志，第44卷，第2期，第TPS609-TPS609页，2026年1月。
{"title":"A phase II study of re-introduction of gemcitabine plus cisplatin in combination with durvalumab after durvalumab maintenance therapy in patients with unresectable or recurrent biliary tract cancer (PRIDE study).","authors":"Kumiko Umemoto, Ryoji Takada, Tomoyuki Satake, Shunsuke Onoe, Satoshi Shimizu, Hiroshi Nakase, Kenro Hirata, Kazuhiko Shioji, Kazuyuki Matsumoto, Ayako Hata, Kenichiro Tanabe, Makoto Ueno, Junji Furuse, Yu Sunakawa","doi":"10.1200/jco.2026.44.2_suppl.tps609","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps609","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS609-TPS609, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"18 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968677","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Vinai Gondi, Erik P. Sulman, Jedd D. Wolchok, Minesh P. Mehta
Journal of Clinical Oncology, Ahead of Print.
临床肿瘤学杂志，印刷前。
{"title":"Reply to: Blood-Brain Barrier Heterogeneity in NRG BN007: Implications for Immunotherapy Delivery","authors":"Andrew B. Lassman, Mei-Yin C. Polley, Fabio M. Iwamoto, Vinai Gondi, Erik P. Sulman, Jedd D. Wolchok, Minesh P. Mehta","doi":"10.1200/jco-25-02821","DOIUrl":"https://doi.org/10.1200/jco-25-02821","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"40 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993087","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Ending the Controversy Around Pretreatment Dihydropyrimidine Dehydrogenase (DPD/DPYD) Testing Heightens the Controversy Over Appropriate Fluoropyrimidine Dosing","authors":"Daniel L. Hertz, Alan P. Venook","doi":"10.1200/jco-25-02629","DOIUrl":"https://doi.org/10.1200/jco-25-02629","url":null,"abstract":"Journal of Clinical Oncology, Ahead of Print. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"1 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145993088","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1200/jco.2026.44.2_suppl.tps799
Isildinha M. Reis, Jashodeep Datta, Yolanda Justal, Peter Joel Hosein
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS799-TPS799, January 2026.
临床肿瘤学杂志，第44卷，第2期，第TPS799-TPS799页，2026年1月。
{"title":"Utility of ctDNA in early switch of first-line mFOLFIRINOX in metastatic pancreatic ductal adenocarcinoma (mPDAC).","authors":"Isildinha M. Reis, Jashodeep Datta, Yolanda Justal, Peter Joel Hosein","doi":"10.1200/jco.2026.44.2_suppl.tps799","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps799","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS799-TPS799, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"266 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968655","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1200/jco.2026.44.2_suppl.tps792
Patricia LoRusso, Ignacio Garrido-Laguna, Benjamin Herzberg, Amita Patnaik, Neel Jitendra Gandhi, Kathryn Smith, Lori Cykowski, Xin Zhi, Diane I. Healey, Vaibhav G. Patel, David S. Hong
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS792-TPS792, January 2026.
临床肿瘤学杂志，第44卷，第2期，TPS792-TPS792页，2026年1月。
{"title":"Phase 1/2 study of ARV-806, a PROTAC KRAS G12D degrader, in KRAS G12D–mutated advanced solid tumors, including pancreatic cancer.","authors":"Patricia LoRusso, Ignacio Garrido-Laguna, Benjamin Herzberg, Amita Patnaik, Neel Jitendra Gandhi, Kathryn Smith, Lori Cykowski, Xin Zhi, Diane I. Healey, Vaibhav G. Patel, David S. Hong","doi":"10.1200/jco.2026.44.2_suppl.tps792","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps792","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS792-TPS792, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"4 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968661","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2026-01-01DOI: 10.1200/jco.2026.44.2_suppl.tps613
Charity Morgan, Ahmet Anil Ozluk, S.M. Qasim Hussaini, Garima Gupta, Darryl Alan Outlaw, Alexander Bray, Midhun Malla, Bassel F. El-Rayes
Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS613-TPS613, January 2026.
临床肿瘤学杂志，第44卷，第2_增刊，TPS613-TPS613页，2026年1月。
{"title":"A phase Ib/II, dose escalation and dose expansion study of valemetostat tosylate (DS-3201b) with atezolizumab and bevacizumab in advanced hepatocellular carcinoma (HCC).","authors":"Charity Morgan, Ahmet Anil Ozluk, S.M. Qasim Hussaini, Garima Gupta, Darryl Alan Outlaw, Alexander Bray, Midhun Malla, Bassel F. El-Rayes","doi":"10.1200/jco.2026.44.2_suppl.tps613","DOIUrl":"https://doi.org/10.1200/jco.2026.44.2_suppl.tps613","url":null,"abstract":"Journal of Clinical Oncology, Volume 44, Issue 2_suppl, Page TPS613-TPS613, January 2026. <br/>","PeriodicalId":15384,"journal":{"name":"Journal of Clinical Oncology","volume":"32 1","pages":""},"PeriodicalIF":45.3,"publicationDate":"2026-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"145968673","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":1,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：